scholarly journals Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort

2018 ◽  
Vol Volume 13 ◽  
pp. 2999-3002 ◽  
Author(s):  
Timm Greulich ◽  
Sina Mager ◽  
Tanja Lucke ◽  
Andreas Rembert Koczulla ◽  
Robert Bals ◽  
...  
Keyword(s):  
Eosinophil Count ◽  
Blood Eosinophil ◽  
Longitudinal Stability ◽  
Blood Eosinophil Count

scholarly journals Is Blood Eosinophil Count a Biomarker for Chronic Obstructive Pulmonary Disease in a Real-World Clinical Setting? Predictive Property and Longitudinal Stability in Japanese Patients

Diagnostics ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 404
Author(s):  
Koichi Nishimura ◽  
Masaaki Kusunose ◽  
Ryo Sanda ◽  
Mio Mori ◽  
Ayumi Shibayama ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Real World ◽  
Clinical Setting ◽  
Eosinophil Count ◽  
Chronic Obstructive ◽  
Blood Eosinophil ◽  
Longitudinal Stability ◽  
Obstructive Pulmonary Disease ◽  
Blood Eosinophil Count

The authors examined predictive properties and the longitudinal stability of blood eosinophil count (BEC) or three strata (<100 cells/mm3, 100–299 cells/mm3 and ≥300 cells/mm3) in patients with chronic obstructive pulmonary disease (COPD) for up to six and a half years as part of a hospital-based cohort study. Of the 135 patients enrolled, 21 (15.6%) were confirmed to have died during the follow-up period. Episodes of acute exacerbation of COPD (AECOPD) were identified in 74 out of 130 available patients (56.9%), and admission due to AECOPD in 35 out of 132 (26.5%). Univariate Cox proportional hazards analyses revealed that almost all the age, forced expiratory volume in 1 s (FEV1) and health status measures using St. George’s Respiratory Questionnaire (SGRQ) Total and COPD Assessment Test (CAT) Score were significantly related to these types of events, but the relationship between age and AECOPD did not reach statistical significance (p = 0.05). Neither BEC nor the three different groups stratified by BEC were significant predictors of any subsequent events. There were no significant differences in the BEC between Visits 1–3 (p = 0.127, Friedman test). The ICC value was 0.755 using log-transformed data, indicating excellent repeatability. In the case of assigning to strata, Fleiss’ kappa was calculated to be 0.464, indicating moderate agreement. The predictive properties of BEC may be limited in a real-world Japanese clinical setting. Attention must be paid to the fact that the longitudinal stability of the three strata is regarded as moderate.

Point-of-care blood eosinophil count in a severe asthma clinic setting

2017 ◽  
Vol 119 (1) ◽  
pp. 16-20 ◽  
Author(s):  
Enrico Heffler ◽  
Giovanni Terranova ◽  
Carlo Chessari ◽  
Valentina Frazzetto ◽  
Claudia Crimi ◽  
...  
Keyword(s):  
Severe Asthma ◽  
Eosinophil Count ◽  
Point Of Care ◽  
Blood Eosinophil ◽  
Blood Eosinophil Count ◽  
Clinic Setting

scholarly journals Blood eosinophil count to predict bronchial eosinophilic inflammation in COPD

2016 ◽  
Vol 47 (5) ◽  
pp. 1562-1564 ◽  
Author(s):  
Florence Schleich ◽  
Jean-Louis Corhay ◽  
Renaud Louis
Keyword(s):  
Eosinophil Count ◽  
Blood Eosinophil ◽  
Eosinophilic Inflammation ◽  
Blood Eosinophil Count

Clinical variables and protein biomarkers associated with blood eosinophil count and asthma in young adults

2021 ◽  
Author(s):  
Maura Kere ◽  
Sophia Björkander ◽  
Susanna Klevebro ◽  
Maria Ödling ◽  
Sandra Ekström ◽  
...  
Keyword(s):  
Young Adults ◽  
Eosinophil Count ◽  
Blood Eosinophil ◽  
Protein Biomarkers ◽  
Blood Eosinophil Count ◽  
Clinical Variables

Evaluation of the peripheral blood eosinophil count as a predictor for fractional exhaled nitric oxide or bronchodilator reversibility test outcome

2021 ◽  
Vol 42 (3) ◽  
pp. 228-234
Author(s):  
Bo Zhao ◽  
Haiming Zheng ◽  
Xiaopan Li ◽  
Rui Zheng
Keyword(s):  
Nitric Oxide ◽  
Roc Curve ◽  
Peripheral Blood ◽  
Eosinophil Count ◽  
Blood Eosinophil ◽  
Test Results ◽  
Fractional Exhaled Nitric Oxide ◽  
Peripheral Blood Eosinophil ◽  
Blood Eosinophil Count ◽  
Feno Level

Objective: This study aimed to explore the usefulness of the peripheral blood eosinophil count (PBEC) in assessing the level of fractional exhaled nitric oxide (FeNO) and predicting bronchodilation test results. Methods: We retrospectively analyzed the data of 384 outpatients who underwent FeNO measurement at our Department of Respiratory and Critical Care Medicine from March to June 2019. The FeNO level was compared among different PBECs to explore the association among them. Furthermore, the sensitivity and specificity of PBECs in predicting bronchodilation test results were assessed by using receiver operating characteristic (ROC) curve analysis. Results: There was a moderate correlation between PBECs and FeNO levels (r = 0.414; p < 0.05). In the subjects with PBECs ≥ 0.3 × 109/L, the median FeNO level was 39 ppb (interquartile range, 22.5‐65.5 ppb), significantly higher than in the subjects with PBECs < 0.3 × 109/L. The area under the ROC curve was 0.707 (p < 0.05). The maximum Youden index (0.348) was at PBECs = 0.205 × 109/L, which achieved sensitivity and specificity of 63% and 71.8%, respectively. Conclusion: PBECs ≥ 0.3 × 109/L can predict a positive bronchodilation test result and a high FeNO level, with a probability of 50% in the subjects with chronic cough and shortness of breath; in the absence of corresponding symptoms and a low PBEC, the predictive value was small. For hospitals not able to conduct FeNO measurements, for outpatients with poor economic conditions, and for patients with confirmed or suspected novel coronavirus disease 2019, the PBEC, in conjunction with a patient's clinical symptoms, can improve the diagnostic accuracy of allergic asthma and assessment of airway inflammation while reducing the risk of infection.

Blood eosinophil count and FeNO to predict benralizumab effectiveness in real-life severe asthma patients

2021 ◽  
pp. 1-12
Author(s):  
Hirofumi Watanabe ◽  
Toshihiro Shirai ◽  
Keita Hirai ◽  
Taisuke Akamatsu ◽  
Hiromasa Nakayasu ◽  
...  
Keyword(s):  
Severe Asthma ◽  
Eosinophil Count ◽  
Real Life ◽  
Blood Eosinophil ◽  
Blood Eosinophil Count ◽  
Asthma Patients

scholarly journals Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review

2020 ◽  
Vol 21 (3) ◽  
pp. 889 ◽  
Author(s):  
Koichi Ando ◽  
Akihiko Tanaka ◽  
Hironori Sagara
Keyword(s):  
Systematic Review ◽  
Eosinophil Count ◽  
Blood Eosinophil ◽  
Efficacy And Safety ◽  
Exacerbation Rate ◽  
Blood Eosinophil Count ◽  
Indirect Treatment Comparison ◽  
Treatment Comparison ◽  
Significant Difference ◽  
Indirect Treatment

No head-to-head trials have compared the efficacy and safety between the licensed dosage and administration dosage of dupilumab and benralizumab for inadequately controlled asthma. We conducted an indirect treatment comparison to estimate differences in the efficacy and safety between dupilumab and benralizumab for inadequately controlled asthma using the Bayesian approach. The primary efficacy endpoint was annual exacerbation rate (AER). A subgroup analysis by blood eosinophil count was also performed. The primary safety endpoint was the incidence of any adverse events (AAEs). The results demonstrate that there was no significant difference in the AER between dupilumab and benralizumab in overall patients and the subgroup with the blood eosinophil count of <150. However, the AER was significantly lower in the dupilumab group than in the benralizumab group in the subgroup with a blood eosinophil count of ≥150 but <300, and ≥300 with the rate ratio and 95% credible interval of 0.51 (0.29–0.92) and 0.58 (0.39–0.84), respectively. There was no significant difference in the AAEs between the dupilumab and benralizumab groups. This indirect treatment comparison indicates that dupilumab is superior to benralizumab in patients with inadequately controlled asthma having higher blood eosinophil counts. A direct comparison is required to provide definitive evidence. Systematic Review Registration: UMIN-CTR no. UMIN000036256.

scholarly journals Blood eosinophil count group shifts and kinetics in severe eosinophilic asthma

2020 ◽  
Vol 125 (2) ◽  
pp. 171-176
Author(s):  
Njira L. Lugogo ◽  
James L. Kreindler ◽  
Ubaldo J. Martin ◽  
Bill Cook ◽  
Ian Hirsch ◽  
...  
Keyword(s):  
Eosinophil Count ◽  
Blood Eosinophil ◽  
Eosinophilic Asthma ◽  
Blood Eosinophil Count ◽  
Severe Eosinophilic Asthma
Sign in / Sign up

Export Citation Format

Share Document